Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Adithya Chennamadhavuni"'
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
For patients with metastatic RAS/RAF wild-type refractory colorectal cancer, the question of anti-EGFR therapy rechallenge often comes up after initial use. However, not all patients derive benefit. It is now well known that these tumors acquire mech
Externí odkaz:
https://doaj.org/article/b50d4641bc3f43f7b9bccb12600489df
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
Immune-related adverse events (irAEs) are a range of complications associated with the use of immune-checkpoint inhibitors (ICIs). Two major classes of ICIs widely used are Cytotoxic T-Lymphocyte Antigen 4 (CTLA4) and Programmed Cell death-1 (PD-1)/P
Externí odkaz:
https://doaj.org/article/2e5bf03940a54ca2a38cf2f71bd39e83
Patient Characteristics and Survival Outcomes of Non-Metastatic, Non-Clear Cell Renal Cell Carcinoma
Autor:
Josiah An, Vignesh T. Packiam, Adithya Chennamadhavuni, Jordan Richards, Jayanshu Jain, Sarah L. Mott, Rohan Garje
Publikováno v:
Frontiers in Oncology, Vol 11 (2022)
BackgroundNon-clear cell renal cell carcinoma (ccRCC) includes histologically and molecularly distinct subtypes such as papillary, chromophobe, collecting duct, and sarcomatoid RCC, with an incidence ranging from 20% to 25%. Oncologic outcomes and th
Externí odkaz:
https://doaj.org/article/1dde99dfdb844dbbb1d343f4e93e3575
Publikováno v:
Frontiers in Oncology, Vol 10 (2020)
Immunotherapy has revolutionized the treatment of both hematological malignancies and solid tumors. The use of immunotherapy has improved outcome for patients with cancer across multiple tumor types, including lung, melanoma, ovarian, genitourinary,
Externí odkaz:
https://doaj.org/article/dc1de87c762941fa85a786fd542c5e60
Autor:
Umang Swami, Adithya Chennamadhavuni, Nicholas Borcherding, Aaron D. Bossler, Sarah L. Mott, Rohan Garje, Yousef Zakharia, Mohammed Milhem
Publikováno v:
Antibiotics, Vol 9, Iss 11, p 740 (2020)
Recently antibiotic exposure has been associated with worse outcomes in patients undergoing treatment with antibodies directed against programmed cell death protein-1 (PD-1). We reviewed data of 1264 patients enrolled at Melanoma Skin and Ocular Tiss
Externí odkaz:
https://doaj.org/article/84ce59a7f372487eb5211a5bd898c6fe
Autor:
Bradley T. Loeffler, Taher Abu Hejleh, Mary Pasquinelli, Timothy L. Sita, Ryan Nguyen, Sarah L. Mott, Tim J. Kruser, Muhammad Furqan, Adithya Chennamadhavuni, Nasser H. Hanna, Melissa Yan, Lawrence Eric Feldman, Nanmeng Yu, Josiah An
Publikováno v:
Translational Lung Cancer Research. 10:3608-3615
Background STK11 mutation (STK11m ) in patients (pts) with stage IV non-small cell lung cancer (NSCLC) is associated with inferior survival and poor response to immune checkpoint inhibitors (ICI). The significance of STK11m in stage III NSCLC pts tre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3ecd1ee7adfc7a01bf19cf21fc86b9f4
https://doi.org/10.21037/tlcr-21-177
https://doi.org/10.21037/tlcr-21-177
Autor:
Tejasvi, Sunkara, Sai Samyuktha, Bandaru, Rajendra, Boyilla, Rajesh, Kunadharaju, Prithvi, Kukkadapu, Adithya, Chennamadhavuni
Publikováno v:
Cureus.
Pancreatic cancer is the third most common cause of cancer death in the United States and eleventh worldwide. The majority of patients present with advanced disease with five-year overall survival of less than 10%. Traditional chemotherapy has been t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::43123f72208bf17c270fb5fb0efa5d21
https://doi.org/10.7759/cureus.22575
https://doi.org/10.7759/cureus.22575
Publikováno v:
Clin Med Res
Introduction: Non-Hodgkin lymphoma is the seventh most common cancer in the United States. It may involve any extranodal organ, although involvement of the genitourinary (GU) tract accounts for
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::440acc9c6bf21eb36f135e2bd9866fef
https://europepmc.org/articles/PMC8231695/
https://europepmc.org/articles/PMC8231695/
Autor:
Josiah, An, Melissa, Yan, Nanmeng, Yu, Adithya, Chennamadhavuni, Muhammad, Furqan, Sarah L, Mott, Bradley T, Loeffler, Timothy, Kruser, Timothy L, Sita, Lawrence, Feldman, Ryan, Nguyen, Mary, Pasquinelli, Nasser H, Hanna, Taher, Abu Hejleh
Publikováno v:
Transl Lung Cancer Res
BACKGROUND: STK11 mutation (STK11(m)) in patients (pts) with stage IV non-small cell lung cancer (NSCLC) is associated with inferior survival and poor response to immune checkpoint inhibitors (ICI). The significance of STK11(m) in stage III NSCLC pts
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::25b76e738d193ca9336c7b26a9745724
https://pubmed.ncbi.nlm.nih.gov/34584860
https://pubmed.ncbi.nlm.nih.gov/34584860
Autor:
Sarah L. Mott, Mohammed M. Milhem, Yousef Zakharia, Nicholas Borcherding, Rohan Garje, Adithya Chennamadhavuni, Umang Swami, Aaron D. Bossler
Publikováno v:
Antibiotics
Antibiotics, Vol 9, Iss 740, p 740 (2020)
Volume 9
Issue 11
Antibiotics, Vol 9, Iss 740, p 740 (2020)
Volume 9
Issue 11
Recently antibiotic exposure has been associated with worse outcomes in patients undergoing treatment with antibodies directed against programmed cell death protein-1 (PD-1). We reviewed data of 1264 patients enrolled at Melanoma Skin and Ocular Tiss
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b20ece036ca3068d4f0fb578781f1abe
http://europepmc.org/articles/PMC7692514
http://europepmc.org/articles/PMC7692514